Voltage Gated Sodium Channel Blockers as Treatment for Prostate Cancer

Categories: “Cancer Therapeutics

Reference #: 2008-018, 2009-002

OTC Contact: Ruchika Nijhara, Ph.D., MBA, CLP (Directory Information | Send a Message)


Voltage Gated Sodium Channels (VGSC or Nav) with known expression in central nervous and cardiac tissue are present in human prostate cancer. This invention encompasses novel sodium channel blockers that inhibit both androgen dependent and independent human prostate cancer. These blockers down-regulate the expression of certain Nav isoform(s) relevant to prostate cancer. Structure Analysis Relationship (SAR) has demonstrated a significant correlation with Nav isoform selectivity. In tumors from prostate cancer patients, a correlation between Gleason Score and isoform specificity has been elucidated, which has led to identification of specific Nav isoforms as biomarkers for prostate cancer. The results of this research demonstrate the potential of Nav targeted therapies for the treatment and diagnosis of human prostate cancer.


Small molecule agents for the treatment and diagnosis of prostate cancer.


Stage of Development

Relevant Publications

No references or resources available.

Patent Status

U.S. Patent No. 7,439,382; Issued October 21, 2008; Additional Applications Filed